Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
Immune responses to the gut microbiota can be used as biomarkers of clinical course in IBD or as targets for the treatment or prevention of the condition.
Decreased microbial diversity and increased abundance of Firmicutes phylum in the respiratory tract may be associated with an increased risk of lung cancer.
The findings suggest that delivery mode, rather than birth canal exposure, has a strong influence on the composition of the infant microbiota.
Modulating the gut microbiota could help to increase Plasmodium-specific immunity, thus reducing disease severity and malaria-associated mortality.
Researches have found that MDD is characterized by disturbances in the gut microbiota and may allow clinicians to better diagnose it.
A two-pronged treatment strategy — consisting of an engineered peptide and an FDA-approved drug — could help to reduce gut inflammation.
The current knowledge of the gut-liver axis in NAFLD may lead to the development of microbiota-based personalized approaches for managing the condition.
A study published in Nature suggests new approaches to improve BMTs as well as treatments for immune-mediated diseases by regulating the gut microbiota.
People with active multiple sclerosis have high levels of particular gut antibodies, called immunoglobulin A (IgA), in the central nervous systems.
Some C. acnes strains harbored genes that encoded a molecule similar in structure to a known antibiotic called berninamycin.
